Larvol Delta - Palladio-Biosciences-Announces-First-Patient-Dosed-With-Lixivaptan-in-The-ALERT-Study-a-Phase-3-Study-of-ADPKD-Patients-Previously-Discontinued-From-Treatment-With-Tolvaptan-Due-to-Liver-Toxicity--

Lixar (lixivaptan) - Palladio

https://www.businesswire.com/news/home/20201117005255/en/Palladio-Biosciences-Announces-First-Patient-Dosed-With-Lixivaptan-in-The-ALERT-Study-a-Phase-3-Study-of-ADPKD-Patients-Previously-Discontinued-From-Treatment-With-Tolvaptan-Due-to-Liver-Toxicity

Nov 17, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next